| BIIB |
Report |
Total Revenue (Q2 2026) |
BEAT |
pred ~$2,530M vs. cons $2,455.5M |
MEDIUM |
| BIIB |
Report |
SYFOVRE + EMPAVELI Combined (Q2 2026) |
BEAT |
pred ~$100M vs. cons $88.95M |
MEDIUM |
| BIIB |
Report |
Non-GAAP EPS (Q2 2026) |
BEAT |
pred ~$2.10 vs. cons $1.97 |
MEDIUM |
| BIIB |
Guide |
FY 2026 Total Revenue (FY 2026) |
BETTER |
guide ~$10.2-10.4B vs. cons $10,032.9M |
MEDIUM |
| BIIB |
Guide |
FY 2026 Non-GAAP EPS (FY 2026) |
UNCHANGED |
guide range straddles cons ~$12.60 |
MEDIUM |
| BIIB |
Guide |
Apellis Growth Trajectory (FY 2026) |
BETTER |
guide high-teen to low-20% growth vs. cons implying mid-teen% |
LOW |
| BIIB |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.5% |
— |
MEDIUM |
| BIIB |
Return |
5-day cumulative residual |
+4.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — estimate revisions track the FY revenue raise; Q3 IPR&D charge already disclosed and will not drag; archetype A 5-day avg +4.22% |
MEDIUM |